9 METERS BIOPHARMA, INC.: Nasdaq/NYSE listing notice — 9 Meters Biopharma receives Nasdaq non-compliance notice for bid price below $1.00

9 METERS BIOPHARMA, INC.

On June 12, 2023, Nasdaq notified 9 Meters that its stock closed below $1.00 for 31 consecutive business days.
Company has 180 calendar days (until Dec 11, 2023) to regain compliance by closing at $1.00 or more for 10 consecutive days.
If not cured, may be eligible for additional 180-day period if meeting other listing standards and provides notice.
No immediate effect on listing; company is evaluating options to regain compliance.
There is no assurance of regaining compliance; delisting risk remains.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

9 METERS BIOPHARMA, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

June 12, 2023, 9 Meters Biopharma, Inc. (the “Company”) was notified by the Nasdaq Stock Market LLC (“Nasdaq”) that for the last 31 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until December 11, 2023, to regain compliance with the Bid Price Rule. If at any time before December 11

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001551986-23-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.